Hangzhou Huadong Medicine Bioengineering Research Center

Hangzhou Huadong Medicine Bioengineering Research Center is the primary R&D subsidiary of Huadong Medicine, specializing in the development of biopharmaceuticals and high-end chemical drugs. The center is a leader in microbial fermentation technology and recombinant protein engineering, with a strong focus on immunosuppressants, metabolic diseases, and oncology. It has successfully developed and commercialized several key products, including cyclosporine, mycophenolate mofetil, and tacrolimus, which have become cornerstones of the Chinese immunosuppressant market. Currently, the center is advancing a robust pipeline of biosimilars and innovative biologics, notably GLP-1 receptor agonists like liraglutide and semaglutide. Its integrated R&D capabilities support the parent company's transition from a traditional pharmaceutical manufacturer to an innovation-driven global healthcare player.